In the first quarter of 2026, the FDA issued nine approvals in oncology, including treatments for blood cancers, pancreatic...
The spring 2026 issue of Cancer Today included articles about using AI chatbots, cancer survivor—and “Survivor” winner—Ethan Zohn, and...
In March, AACR's journals editors highlighted studies on the development of pediatric leukemia, the use of low-dose tamoxifen, and...
In November 2025, AACR on Campus events were held in Taiwan where local early-career researchers engaged with global leaders...
Learn about smoldering myeloma and the first treatment approved by the U.S. Food and Drug Administration to prevent its...
AACR journals editors Robert Kruger and Elizabeth McKenna share how they're working to strengthen ties with the research...
Three innovative studies at AACR IO 2026 presented new ways for CAR T cells and antibody-lectin chimeras to tackle...
Epidemiologist Elizabeth A. Platz explains what goes into calculating cancer risk estimates, such as rate ratio, hazard ratio, and...
At AACR IO 2026, Nobel laureate Fred Ramsdell explained the research history of regulatory T cells (Tregs) and the...
In February, the editors of AACR's journals highlighted studies on the FDA’s accelerated approval pathway, how metabolism impacts prostate...
Elizabeth M. Jaffee and Philip D. Greenberg opened AACR IO 2026 with a look at cancer vaccines and the...